Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,396,658
  • Shares Outstanding, K 55,714
  • Annual Sales, $ 2,162 M
  • Annual Income, $ 523,370 K
  • 60-Month Beta 1.05
  • Price/Sales 3.89
  • Price/Cash Flow 6.80
  • Price/Book 2.38
Trade JAZZ with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 3.72
  • Number of Estimates 5
  • High Estimate 4.01
  • Low Estimate 3.45
  • Prior Year 4.04
  • Growth Rate Est. (year over year) -7.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
140.00 +7.65%
on 11/30/20
157.66 -4.41%
on 11/05/20
-6.62 (-4.21%)
since 11/04/20
3-Month
134.02 +12.45%
on 09/08/20
158.98 -5.20%
on 11/04/20
+19.01 (+14.43%)
since 09/04/20
52-Week
86.88 +73.47%
on 03/23/20
158.98 -5.20%
on 11/04/20
+2.55 (+1.72%)
since 12/04/19

Most Recent Stories

More News
JAZZ's Zepzelca Combo SCLC Study Fails, Drug Still Promising

JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug. Stock up.

IRWD : 11.98 (+3.45%)
JAZZ : 150.71 (-0.19%)
BLCM : 3.09 (+0.98%)
CTLT : 95.40 (+2.06%)
Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line

, /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, randomized, controlled study evaluating...

PHM : 42.06 (-2.57%)
JAZZ : 150.71 (-0.19%)
Jazz (JAZZ) Down 3.7% Since Last Earnings Report: Can It Rebound?

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JAZZ : 150.71 (-0.19%)
Can Value Investors Consider Jazz Pharmaceuticals (JAZZ) Stock?

Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.

JAZZ : 150.71 (-0.19%)
Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors

, Nov. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that and , M.D. have been appointed to the Company's Board of Directors, effective .

JAZZ : 150.71 (-0.19%)
3 Biotech Stocks Set to Soar in 2021

As Pfizer (PFE) announced that its COVID-19 vaccine candidate is 90% effective, biotech stocks are on fire. These stocks have seen a bull-run since the beginning of 2020 and are expected to witness the...

JAZZ : 150.71 (-0.19%)
ARWR : 65.29 (+2.05%)
UTHR : 133.47 (+2.72%)
NTLA : 43.44 (+1.21%)
Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference

, /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare conference:

JAZZ : 150.71 (-0.19%)
Data at ASH 2020 Annual Meeting Highlights Jazz Pharmaceuticals' Commitment to Advancing Hematology/Oncology Research

, /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 11 company-sponsored abstracts, in addition to two abstracts from collaboration trials with The MD Anderson Cancer Center...

JAZZ : 150.71 (-0.19%)
Jazz Pharma (JAZZ) Beats on Q3 Earnings, Ups Sales Guidance

Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.

ENDP : 5.38 (-1.47%)
JAZZ : 150.71 (-0.19%)
USNA : 78.66 (+1.30%)
SAVA : 7.73 (+3.20%)
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of 6.95% and 4.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

JAZZ : 150.71 (-0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 155.72
1st Resistance Point 153.22
Last Price 150.71
1st Support Level 148.42
2nd Support Level 146.12

See More

52-Week High 158.98
Last Price 150.71
Fibonacci 61.8% 131.44
Fibonacci 50% 122.93
Fibonacci 38.2% 114.42
52-Week Low 86.88

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar